Mdma molecule:

Image from PubChem

Mdma Clinical Trials

An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adults

To see complete record on, please visit this link

Id: 2017-001169-26

Organisation Name: SyneuRx International (Taiwan) Corp

Start Date: 2019-04-09

Completion Date: Ongoing

Brief Summary: The primary objective of this study is to evaluate the effectiveness of NaBen® (sodium benzoate) (1000 mg/day) compared to Placebo (0 mg/day), in improving symptoms associated with schizophrenia in adults.

Country: United States

Total execution time in seconds: 0.18906807899475